89Zr-LNCab103

89Zr-LNCab103 is a **zirconium-89 (^89Zr) radiolabeled engineered antibody fragment** developed for positron emission tomography (PET) imaging. The antibody fragment, LNCab103, is designed to target **HER2 (human epidermal growth factor receptor 2)**, a receptor commonly overexpressed in various cancers. The Fc region of the antibody is modified or removed, resulting in a lower molecular weight and shorter circulation half-life, which may improve imaging properties and reduce background signal. 89Zr-LNCab103 is being investigated for its clinical utility in the diagnosis and screening of **HER2-positive cancers**, specifically in malignancies such as breast cancer, gastric cancer, and urothelial carcinoma. It is administered intravenously, and the typical imaging dose is about 1-3 mCi. The agent is currently in early phase clinical development for oncological PET imaging applications[1][5][8][9].